Ospedale San Raffaele S.R.L.

Lombardia

UEI
D9ECADLUG6H3
CAGE
AL154
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Foreign Owned
  • For Profit Organization
  • Hospital
Entity structure
Partnership or Limited Liability Partnership
Other NAICS codes in SAM.gov
SAM.gov registration date
Physical address
Via Olgettina, 60, 20132 Milano MI, Italy
Website
hsr.it
Founded
1971
Employees
1K-5K
Estimated annual revenue
$1B-$10B
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
  4. Health Care Services
SIC code
80 Health Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
JSI Research & Training Institute Inc. Technical assistance and guidance to the Kyrgyz National TB Program and National TB Reference Laboratory related to Next Generation Sequencing of M.… 72011524CA00003 $97,543

Similar vendors

About the company

Ospedale San Raffaele S.R.L. is a clinical, scientific, and university center providing medical and scientific excellence since 1971. The hospital offers services including research and development in areas such as immunotherapy, neural stem cell therapeutics, kidney disease treatment, and modulation of the immune system's response to transplanted tissue.

Ospedale San Raffaele S.R.L. has received four prime federal grants from the Department of the Army Medical Command through the Military Medical Research and Development program, which aims to transform military and public healthcare. These grants funded research and development projects related to engineering thymic selection to control alloreactive T cells ($650,000 over three years from 2022), developing CRISPR-engineered human neural stem cell therapeutics to address remyelination failure in multiple sclerosis ($217,280 over two years from 2022), developing 2-deoxy-D-glucose for the treatment of polycystic kidney disease ($8,686,082 over four years from 2022), and studying the regulation of human endogenous retroviruses in cancer immunotherapy ($277,695 over three years from 2020).

Ospedale San Raffaele S.R.L. has not received any prime federal contract awards. As a subcontractor, Ospedale San Raffaele S.R.L. supported the development of drug resistance survey protocols, data collection tools, a pilot sentiment surveillance system, and a five-year tuberculosis lab roadmap, subcontracted under a prime contract between ICF Incorporated, L.L.C. and an unspecified federal agency.

Quick answers

Is Ospedale San Raffaele S.R.L. registered in SAM.gov?

Yes. Ospedale San Raffaele S.R.L.'s SAM.gov registration is active through July 22, 2027.

What is Ospedale San Raffaele S.R.L.'s most recent federal award?

Ospedale San Raffaele S.R.L.'s most recent federal grant award is Engineering thymic selection to control the development of alloreactive t cells and promote VCA acceptance (W81XWH2210977), from Defense Health Agency, on September 30, 2022.

On GovTribe

See Ospedale San Raffaele S.R.L.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors